(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/152821 A1

(51) International Patent Classification:
C07D 401/04 (2006.01) *C07D 417/14* (2006.01)
C07D 401/14 (2006.01) *A61P 35/00* (2006.01)
C07D 405/14 (2006.01) *A61K 31/4439* (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:
PCT/EP2022/050699

(22) International Filing Date:
13 January 2022 (13.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

00025/21	13 January 2021 (13.01.2021)	CH
00386/21	14 April 2021 (14.04.2021)	CH
00655/21	04 June 2021 (04.06.2021)	CH
63/281,049	18 November 2021 (18.11.2021)	US

(71) Applicant: **MONTE ROSA THERAPEUTICS AG** [CH/CH]; Klybeckstrasse 191, 4057 Basel (CH).

(72) Inventors: **FASCHING, Bernhard**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH). **RYCKMANS, Thomas**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH). **FLOHR, Alexander**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH). **RITZÉN, Andreas**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH). **HARVEY, Freya**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH). **MCALLISTER, Laura**; c/o Monte Rosa Therapeutics AG, Klybeckstrasse 191, 4057 Basel (CH).

(74) Agent: **RENTSCH PARTNER AG**; Kirchenweg 8, Postfach, 8034 Zürich (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ISOINDOLINONE COMPOUNDS

(57) Abstract: Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula (I). These compounds find use as modulators of cereblon, in particular in the treatment of abnormal cell growth in mammals, especially humans.

Figure 1A





(I)

WO 2022/152821 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*